1704
N. D. Chaurasiya et al. / Bioorg. Med. Chem. Lett. 22 (2012) 1701–1704
2. Johnson, J. P. Biochem. Pharmacol. 1968, 17, 1285.
3. Cesura, A. M.; Bos, M.; Galva, M. D.; Kettler, R.; Ad Prada, M. Mol. Pharmacol.
1989, 20, 358.
4. Knoll, J.; Magyor, K. Adv. Biochem. Psychopharmacol. 1972, 5, 393.
5. Cesura, A. M.; Imhof, R.; Galva, M. D.; Kettler, R.; Ad Prada, M. Pharmacol. Res.
Commun. 1988, 20, 51.
6. Baldessarini, R. J. In Goodman and Gilman’s ‘The Pharmacological Basis of
Therapeutics’; Hardman, J. C., Limbird, L. E., Eds.; Elsevier: Amsterdam, 1983; pp
441–465.
MAO-A and B activity. MAO-activity was assessed by a modification of the
fluorometric method of Krajl22 and was adopted for 96 well plate’s format. The
200
(5
l
l reaction mixtures containing recombinant human MAO-A or MAO-B
l
g/ml) and the test compounds in potassium phosphate buffer (100 mM; pH
7.4) were pre-incubated at 37 °C for 15 min. The reactions with positive control
wells with standard MAO inhibitors and controls without inhibitors were also
set up simultaneously. The reaction was initiated by addition of kynuramine
(250
lM) in potassium phosphate buffer (100 mM; pH 7.4) and incubated
further at 37 °C for 20 min. After incubation the reaction was stopped by the
7. Bortolato, M.; Chen, K.; Shih, J. C. Adv. Drug Delivery Rev. 2008, 60, 1527.
8. Boulton, A. A.; Yu, P. H.; Davis, B. A.; Paterson, I. A.; Li, X. M.; Juorio, A. V.;
Durden, D. A.; Dyck, L. E. In Catecholamine; Goldstein, D. G., Eisenhoper, G.,
McCarty, R., Eds.; Academic Press: New York, 1998; pp 308–311.
9. Vindis, C.; Seguelas, M.; Bianchi, P.; Parini, A.; Cambon, C. Biochem. Biophys. Res.
Commun. 2000, 271, 181.
10. Blackwell, B.; Marley, E.; Price, J.; Taylor, D. Br. J. Psychiatry. 1967, 113, 349.
11. Volz, H. P.; Gleiter, C. M. Drugs Aging 1998, 13, 341.
12. Yamada, M.; Yasuhara, H. Neurotoxicology 2004, 25, 215.
13. Carmo, H.; Hengstler, J. G.; de Boer, D.; Ringel, M.; Remiao, F.; Carvalho, F.;
Fernandes, E.; dos Reys, L. A.; Oesch, F.; de Lourdes, B. M. Toxicology 2005, 206,
75.
addition of 75
spontaneously
l
l of 2 N NaOH. The deaminated product of kynuramine, which
cyclizes to 4-hydroxyquinoline, was determined
fluorometrically at 320 nm excitation and 460 nm emission wavelengths in a
plate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA, USA). Wells
receiving no test compounds were used as controls to calculate the inhibition
percentage. The IC50 values were computed from the dose response inhibition
curves prepared by GraphP.
22. Karjl, M. Biochem. Pharmacol. 1965, 14, 1683.
23. Ganesan, S.; Tekwani, B. L.; Sahu, R.; Tripathi, L. M.; Walker, L. A. Toxicol. Appl.
Pharmacol. 2009, 241, 14.
24. Brossi, A.; Millet, P.; Landan, I.; Banbenck, M. E.; Abell, C. W. FEBS Lett. 1987, 2,
291.
14. Constantino, L.; Paixao, P.; Moreira, R.; Portela, M. J.; D Rosario, V. E.; Iley, J. Exp.
Toxicol. Pathol. 1999, 51, 299.
15. Rochat, B.; Kosel, M.; Boss, G.; Testa, B.; Gillet, M.; Baumann, P. Biochem.
Pharmacol. 1998, 56, 15.
25. Berg, D. V. D.; Zoellner, K. R.; Malan, S. F.; Terre’ Blanche, G.; Castagnoli, N., Jr.;
Bergh, J. J.; Petzer, J. P. Bioorg. Med. Chem. 2007, 15, 3692.
26. Binda, C.; Hubalek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. J. Proc. Natl.
Acad. Sci. U.S.A. 2003, 67, 55.
16. Obach, R. S.; Cox, L. M.; Tremaine, L. M. Drug Metab. Dispos. 2005, 33, 262.
17. Salva, M.; Jansat, M.; Martinz-Tobed, A.; Palacios, J. M. Drug. Metab. Dispos.
2003, 31, 404.
18. McChesney, J. D.; Nanayakkara, D. N.; Bartlett, M.; Ager, A. L. U.S. Patent
6,376,511, 2002.
27. Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D. E.; Mattevi,
A. J. Med. Chem. 2004, 47, 1767.
28. Hubalek, F.; Binda, C.; A., khalil; Li, M.; Mattevi, A.; Castagnoli, N., Jr.;
Edmondson, D. E. J. Biol. Chem. 2005, 280, 15761.
29. Colibus, L. D.; Li, M.; Binda, C.; Lusting, A.; Edmondson, D. E.; Mattevi, A. Proc.
Natl. Acad. Sci. U.S.A. 2005, 102, 12684.
30. Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubalik, F. Curr. Med. Chem.
2004, 11, 1983.
19. Nanayakkara, N. P.; Ager, A. L., Jr.; Bartlett, M. S.; Yardley, V.; Croft, S. L.; Khan, I.
A.; McChesney, J. D.; Walker, L. A. Antimicrob. Agents Chemother. 2008, 52, 2130.
20. Materials: Recombinant human MAO-A and
B were obtained from BD
Biosciences (Bedford, MA, USA). Kynuramine bromide, 4-hydroxyquinoline,
clorgyline and R (À) deprenyl were purchased from Sigma (St. Louis, MO, USA).
21. Methods: An in vitro assay was designed to measure the effect of primaquine
31. Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D. E.; Mattevi, A. Proc.
Natl. Acad. Sci. U.S.A. 2003, 100, 9750.
32. Ogunrombi, M. O.; Malan, S. F.; Terre Blanche, G.; Castagnoli, N., Jr.; Bergl, J. J.;
Petzer, J. P. Bioorg. Med. Chem. 2008, 16, 2463.
analogs on MAO-A and
B
activity. Primaquine analogs (10À9 to 10À2 M),
clorgyline and deprenyl (10À12 to 10À5 M) were tested for inhibition of human